LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.

ABSTRACT:

Introduction

LY3045697 is a potent and selective aldosterone synthase (CYP11B2) inhibitor that was developed as a safer alternative to mineralocorticoid receptor antagonists. Effects of LY3045697 on aldosterone and cortisol synthesis, as well as potassium ion homeostasis, were evaluated in two clinical studies in healthy subjects.

Materials and methods

Two incomplete, placebo-controlled crossover-design clinical studies examined safety, pharmacodynamics, and pharmacokinetics under single and repeated dose conditions in healthy subjects. Pharmacodynamics was assessed following oral potassium challenge and intravenous adrenocorticotropic hormone procedures with spironolactone 25 mg/d as an active comparator.

Results

A total of 51 subjects participated in the two studies

SUBMITTER: Sloan-Lancaster J 

PROVIDER: S-EPMC5843917 | biostudies-literature | 2017 Jul-Sep

REPOSITORIES: biostudies-literature